Acute pancreatitis induced by combined use of liraglutide and empagliflozin
10.3760/cma.j.cn114015-20191210-01009
- VernacularTitle:利拉鲁肽与恩格列净联用致急性胰腺炎
- Author:
Kai ZHANG
1
;
Yingchao TIAN
;
Bingqing ZENG
;
Zhihui TANG
Author Information
1. 江西省肿瘤医院药剂科，南昌 330029
- Publication Type:Journal Article
- Keywords:
Pancreatitis;
Incretins;
Liraglutide;
Sodium-glucose transporter 2 inhibitors;
Empagliflozin
- From:
Adverse Drug Reactions Journal
2020;22(10):601-602
- CountryChina
- Language:Chinese
-
Abstract:
A 26-year-old male patient with type 2 diabetes mellitus was given liraglutide (0.6 mg/d) on the basis of insulin combined with metformin because of the poor therapeutic effect. Four days later, the dose of liraglutide was doubled and empagliflozin (10 mg orally, once daily) was added. The next day, the patient developed nausea, vomiting, and abdominal pain accompanied by elevated serum amylase and lipase (peak levels were 1 048 U/L and 26 U/L, respectively). Acute pancreatitis was diagnosed, all hypoglycemic drugs were discontinued, and fasting, gastrointestinal decompression, intravenous fluid infusion, continuous infusion of low-dose insulin, and symptomatic treatments with lansoprazole and somatostatin were given. Three days later, the patient′s symptoms were relieved, and serum amylase and lipase levels returned to normal. Ten days later, the hypoglycemic drug was changed to subcutaneous injection of insulin aspart 30 injection (24 U in the morning and 16 U in the evening) before meals and oral metformin 0.5 g thrice daily. His blood glucose was controlled and no symptoms of pancreatitis recurred. Therefore, it was considered that the patients′ pancreatitis might be related to the combined use of liraglutide and empagliflozin.
